SlideShare ist ein Scribd-Unternehmen logo
1 von 9
Downloaden Sie, um offline zu lesen
Summary of Transactions with FMC:
Divestiture of Certain Crop Protection
Assets and Acquisition of FMC’s Health
& Nutrition Business
March 31, 2017
2
Cautionary Notes on Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-
looking statements often address expected future business and financial performance and financial condition, and often contain words
such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or
negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as
statements about the consummation of the proposed merger of equals transaction with The Dow Chemical Company (the “DowDuPont
Merger”) and the proposed transaction with FMC Corporation (FMC) and the anticipated benefits thereof. These and other forward-
looking statements, including the failure to consummate the DowDuPont Merger or the proposed transaction or to make or take any
filing or other action required to consummate such transactions in a timely manner or at all, are not guarantees of future results and are
subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-
looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) the completion of the
DowDuPont Merger and the proposed transaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated
tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance,
indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and
growth of the new combined company’s or the Health and Nutrition business’s operations and other conditions to the completion of the
DowDuPont Merger and the proposed transaction, (ii) the possibility that the DowDuPont Merger and the proposed transaction may not
close, including because the various approvals, authorizations and declarations of non-objections from certain regulatory and
governmental authorities with respect to either the DowDuPont Merger or the proposed transaction may not be obtained, on a timely
basis or otherwise, including that these regulatory or governmental authorities may not approve of FMC as an acceptable purchaser of
the Ag business in connection with the proposed transaction or may impose conditions on the granting of the various approvals,
authorizations and declarations of non-objections, including requiring the respective Dow, DuPont and FMC businesses, including the
Health and Nutrition business (in the case of DuPont) and the Ag business (in the case of FMC), to divest certain assets if necessary to
obtain certain regulatory approvals or otherwise limiting the ability of the combined company to integrate parts of the Dow and DuPont
businesses and/or the DuPont and Health and Nutrition businesses, (iii) the ability of DuPont to integrate the Health and Nutrition
business successfully and to achieve anticipated synergies, (iv) potential litigation or regulatory actions relating to the DowDuPont
Merger or the proposed transaction that could be instituted against DuPont or its directors, (v) the risk that disruptions from the
3
Cautionary Notes on Forward Looking Statements, Continued
DowDuPont Merger or the proposed transaction will harm DuPont’s business, including current plans and operations, (vi) the ability of
DuPont to retain and hire key personnel, (vii) potential adverse reactions or changes to business relationships resulting from the
announcement or completion of the DowDuPont Merger or the proposed transaction, (viii) uncertainty as to the long-term value of
DowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions, (x) legislative, regulatory and
economic developments, (xi) potential business uncertainty, including changes to existing business relationships, during the pendency of
the DowDuPont Merger or the proposed transaction that could affect DuPont’s financial performance, (xii) certain restrictions during the
pendency of the DowDuPont Merger or the proposed transaction that may impact DuPont’s ability to pursue certain business
opportunities or strategic transactions and (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of
terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well
as other risks associated with the DowDuPont Merger or the proposed transaction, are or will be more fully discussed in (1) DuPont’s
most recently filed Form 10-K, 10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and (3) the joint proxy
statement/prospectus included in the Registration Statement filed with the SEC in connection with the DowDuPont Merger. While the
list of factors presented here is, and the list of factors presented in the relevant Form 10-K, 10-Q and 8-K reports and the Registration
Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and
uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements.
Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include,
among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which
could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. DuPont
assumes no obligation to publicly provide revisions or updates to any forward looking statements, whether as a result of new
information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other
applicable laws.
Adjusted EBITDA Financial Information
This document includes financial information described as “Adjusted EBITDA”, which is a financial term based on earnings before
interest, taxes, depreciation and amortization. Adjusted EBTIDA does not conform to U.S. generally accepted accounting principles
(GAAP) and is considered a non-GAAP measure. The Adjusted EBITDA presented represents management’s best estimate of 2016
financial performance for the portion of DuPont’s business to be divested inclusive of certain assumptions regarding allocations of costs
and therefore a directly comparable measure that would be considered calculated and presented in accordance with GAAP is not
available.
4
• DuPont to sell cereal broadleaf herbicides and chewing
insecticides, together with certain crop protection R&D
capabilities and early stage pipeline initiatives to FMC
Corporation ("FMC")
• DuPont to acquire substantially all of FMC’s Health &
Nutrition business, including food ingredients and
pharmaceutical excipients
• DuPont to receive $1.6B from FMC reflecting difference in
asset value; $1.2B in cash, $0.4B in working capital
• Transactions contingent on DowDuPont merger of equals
• Significant progress on DowDuPont merger of equals
— Targeted merger to close by August 31, 2017
— Targeted close of transactions with FMC in 4Q 2017
— ~$3B of expected DowDuPont merger cost synergies
and $1B of growth synergies preserved
Summary of Transactions1
FMC Health & Nutrition
2016 Sales: $707MM
2016 Adjusted EBITDA2: $228MM
Select Herbicides
Select Insecticides
Certain Crop Protection R&D
Capabilities and Early Stage Discovery
Pipeline
2016 Sales: ~$1.4B
2016 Adjusted EBITDA3: ~$450MM
1 Subject to satisfaction of closing conditions, including receipt of regulatory approval
2 Based on information as disclosed in FMC’s 2016 Form 10-K filing. EBITDA is calculated based upon 2016 FMC’s H&N operating profit less segment depreciation & amortization.
3 Adjusted EBITDA represents management’s estimate of 2016 earnings for the product lines and R&D organization and pipeline, including certain allocations, to be divested before interest, taxes, depreciation &
amortization.
$1.625B = Difference in
asset value
Cash Payment to DuPont by FMC 1,200$
DuPont Retains Certain Working Capital ~425
Consideration to DuPont in Addition to FMC's H&N business 1,625$
Transaction Economics ($MM)
5
DowDuPont’s Strong Global Pure-Play Agriculture Business
Dow
Agriculture
DuPont
Agriculture
Crop
Protection
Seeds &
Traits
DuPont Agriculture Planned Divestiture
2016 Sales $1.4B
1Based on net sales as reported in DuPont’s and Dow’s respective 2016 Form 10-K filings.
2 Late stage defined as pipeline in the following phases: (3) Advanced Development, (4) Pre-Launch, and (L) Launch, as outlined in the presentation at the Bank of America Merrill Lynch conference on March 1, 2017.
Crop
ProtectionSeeds &
Traits
DuPont
Agriculture
Dow
Agriculture
Agriculture Business Before Planned Divestiture
2016 Net Sales1: $15.7B
Agriculture Business After Planned Divestiture
2016 Net Sales1: $14.3B
DowDuPont’s Agriculture Business Will Have:
— A strong, balanced, pure-play profile with a
comprehensive and diverse seed, trait, and crop
protection portfolio and exceptional growth
opportunity
— Strong IP-protected portfolio of crop protection assets,
including insect control, cereal weed control, broadleaf
and grass control, and disease control
— Industry-leading soy and corn selective herbicide
offering and strong market share position in cereal
crops
— Integrated approach to increase crop productivity by
leveraging innovative technologies on a foundation of
agronomic, biotechnology, and digital solutions
— Enhanced scale, multiple routes-to-market enabling
deeper customer intimacy and delivery of complete
crop productivity solutions
Planned Divestiture to Include:
— DuPont’s cereal broadleaf herbicides portfolio
— DuPont’s chewing insecticides portfolio: Rynaxypyr®,
Cyazypyr® and Indoxacarb
— DuPont’s Crop Protection research and development
pipeline and organization, excluding seed treatment,
nematicides, and late-stage R&D programs1, which
DuPont will continue to develop and bring to market,
and excluding personnel needed to support marketed
products and R&D programs that will remain with
DuPont
6

1. This product is fully approved in the U.S. and Canada. Traits included in these products may or may not be approved in all global markets.
Combination Creates Step-Change Capability to Drive Crop Productivity
Strong portfolio of seed and crop protection
solutions to increase grower profitability
CropProtectionGermplasm/Traits
Seed Brands Traits
InsecticidesHerbicides Fungicides
Other Offerings
Advanced Technologies
Specialty
Insect
Control
Portfolio
1

Planned divestiture maintains the strategic logic
and value creation potential of the merger
Broad Seed Offering to Drive Yield Improvements
— Leading seed portfolio based on elite
germplasm delivered through traditional and
advanced breeding techniques
— Strong, diverse trait offerings
Innovative Crop Protection Portfolio
— Broad portfolio of herbicide, insecticide, and
fungicide offerings
— Comprehensive pipeline addressing global
resistance
— Leadership position in diverse markets
globally
Expanding Portfolio of Diverse Technologies
— Robust seed treatment offering leveraging
seed, crop protection and development
expertise
— Prominent digital ag offering providing solid
grower returns
7
 High-margin, high-quality business exposed to attractive demographic
macro tailwinds in Health & Nutrition
 Products for nutrition market providing texture, structure and physical
stability solutions that thicken and stabilize food products
 Formulation ingredients serving the health excipient industry that function
as binders, disintegrants and controlled-release compounds
 Complementary businesses with new opportunities for growth
 Greater offerings within DuPont’s existing texturants business; provides
expertise in key areas such as cellulosics and expanded raw material access
 Diversifies DuPont’s N&H portfolio via addition of pharmaceutical excipients
platform; brings market and customer access to pharmaceutical industry
 Creates opportunities for incremental synergies for Specialty Products
Transaction Strengthens DowDuPont’s Innovation-Driven
Specialty Products Platform
2016
Net Sales1
FMC Health & Nutrition2
Nutrition
Ingredients
Health
Excipients
~$0.7B
Functional Health
Ingredients
~$0.2B EBITDA
Electronics &
Communications
Industrial BiosciencesProtection Solutions Nutrition & Health
~$3B
Aramids
Nonwovens
Solid
Surfaces
~$1.5B
Enzymes
Biomaterials ~$4B
Nutrition
Health
FMC H&N
Process
Technologies
1 Based on net sales as reported in DuPont’s and Dow’s respective 2016 Form 10-K filings.
2 Based on information as disclosed in FMC’s 2016 Form 10-K filing. EBITDA is calculated based upon 2016 FMC’s H&N operating profit less segment depreciation & amortization.
~$4B
8
Specialty Products to Capitalize on Global Megatrends to Deliver
Organic Growth Across Portfolio
Resulting in the
need for…
Engineered
materials
that protect people,
processes and the
environment
Biotechnology
solutions
for large-scale
industrial processes
Key Global
Megatrends Leading Positions
• Aramid fibers and paper
• Nonwoven films and fabrics
• Protective garments
• Industrial enzymes
• Advanced biofuels
• Sulfuric acid technology
Electronic materials
that enable
miniaturization,
connectivity and
versatility
• Solar PV materials
• Circuit packaging materials
• Semicon fab materials
Safe,
nutritious and
healthy foods
• Probiotics & cultures
• Systems and texturants
• Specialty proteins
Electronics &
Communications
Industrial
Biosciences
Protection
Solutions
Nutrition
& Health
Connectivity
and
functionality
Protection and
sustainable
development
Emerging
needs in new
geographies
Improved
health and
nutrition
Renewable
energy
and materials
9
Copyright © 2017 DuPont. All rights reserved.
The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and
all products, unless otherwise noted, denoted with ® or TM are trademarks
or registered trademarks of E. I. du Pont de Nemours and Company.
+Images reproduced by E. I. du Pont de Nemours and Company
under license from the National Geographic Society.

Weitere ähnliche Inhalte

Was ist angesagt?

Du pont 3q16_slides_final
Du pont 3q16_slides_finalDu pont 3q16_slides_final
Du pont 3q16_slides_finalDupontInv
 
Oem presentation oct 23, 2013 final
Oem presentation oct 23, 2013 finalOem presentation oct 23, 2013 final
Oem presentation oct 23, 2013 finalFinningInternational
 
2016 baml conference final
2016 baml conference   final2016 baml conference   final
2016 baml conference finalDupontInv
 
Du pont 4q15 slides final
Du pont 4q15 slides finalDu pont 4q15 slides final
Du pont 4q15 slides finalDupontInv
 
Impax third quarter 2017 earnings call presentation
Impax third quarter 2017 earnings call presentation Impax third quarter 2017 earnings call presentation
Impax third quarter 2017 earnings call presentation impax-labs
 
Finning Canada Investor Tour Presentations
Finning Canada Investor Tour PresentationsFinning Canada Investor Tour Presentations
Finning Canada Investor Tour PresentationsFinningInternational
 
J.p. morgan 2018 healhcare conference
J.p. morgan 2018 healhcare conferenceJ.p. morgan 2018 healhcare conference
J.p. morgan 2018 healhcare conferenceimpax-labs
 
Cibc whistler conference presentation print final
Cibc whistler conference presentation print finalCibc whistler conference presentation print final
Cibc whistler conference presentation print finalFinningInternational
 
Toronto, montreal presentation mar 29 31, 2016-final_print
Toronto, montreal presentation mar 29 31, 2016-final_printToronto, montreal presentation mar 29 31, 2016-final_print
Toronto, montreal presentation mar 29 31, 2016-final_printFinningInternational
 
Q3 Financial Report Conference Call Presentation Slides
Q3 Financial Report Conference Call Presentation Slides Q3 Financial Report Conference Call Presentation Slides
Q3 Financial Report Conference Call Presentation Slides TeckResourcesLtd
 
September 2016 general investor presentationv v final 9 14-16
September 2016 general investor presentationv v final 9 14-16September 2016 general investor presentationv v final 9 14-16
September 2016 general investor presentationv v final 9 14-16irbgcpartners
 
Final q2 fy16 quarterly earnings presentation
Final q2 fy16 quarterly earnings presentationFinal q2 fy16 quarterly earnings presentation
Final q2 fy16 quarterly earnings presentationrockwell_collins
 
4 q15 slides _final.pptx
4 q15 slides _final.pptx4 q15 slides _final.pptx
4 q15 slides _final.pptxSysco_Investors
 
southern 2006 4th
southern 2006 4thsouthern 2006 4th
southern 2006 4thfinance17
 
Teck’s Q2 2019 Financial Results and Investors’ Conference Call
Teck’s Q2 2019 Financial Results and Investors’ Conference CallTeck’s Q2 2019 Financial Results and Investors’ Conference Call
Teck’s Q2 2019 Financial Results and Investors’ Conference CallTeckResourcesLtd
 
BP 1Q 2020 Financial results
BP 1Q 2020 Financial results BP 1Q 2020 Financial results
BP 1Q 2020 Financial results bp
 
BP 3Q 2019 results presentation
 BP 3Q 2019 results presentation BP 3Q 2019 results presentation
BP 3Q 2019 results presentationbp
 

Was ist angesagt? (20)

Du pont 3q16_slides_final
Du pont 3q16_slides_finalDu pont 3q16_slides_final
Du pont 3q16_slides_final
 
Oem presentation oct 23, 2013 final
Oem presentation oct 23, 2013 finalOem presentation oct 23, 2013 final
Oem presentation oct 23, 2013 final
 
2016 baml conference final
2016 baml conference   final2016 baml conference   final
2016 baml conference final
 
Du pont 4q15 slides final
Du pont 4q15 slides finalDu pont 4q15 slides final
Du pont 4q15 slides final
 
Impax third quarter 2017 earnings call presentation
Impax third quarter 2017 earnings call presentation Impax third quarter 2017 earnings call presentation
Impax third quarter 2017 earnings call presentation
 
Finning Canada Investor Tour Presentations
Finning Canada Investor Tour PresentationsFinning Canada Investor Tour Presentations
Finning Canada Investor Tour Presentations
 
Fort mckaypresentation web
Fort mckaypresentation webFort mckaypresentation web
Fort mckaypresentation web
 
J.p. morgan 2018 healhcare conference
J.p. morgan 2018 healhcare conferenceJ.p. morgan 2018 healhcare conference
J.p. morgan 2018 healhcare conference
 
Cibc whistler conference presentation print final
Cibc whistler conference presentation print finalCibc whistler conference presentation print final
Cibc whistler conference presentation print final
 
Toronto, montreal presentation mar 29 31, 2016-final_print
Toronto, montreal presentation mar 29 31, 2016-final_printToronto, montreal presentation mar 29 31, 2016-final_print
Toronto, montreal presentation mar 29 31, 2016-final_print
 
Q3 Financial Report Conference Call Presentation Slides
Q3 Financial Report Conference Call Presentation Slides Q3 Financial Report Conference Call Presentation Slides
Q3 Financial Report Conference Call Presentation Slides
 
September 2016 general investor presentationv v final 9 14-16
September 2016 general investor presentationv v final 9 14-16September 2016 general investor presentationv v final 9 14-16
September 2016 general investor presentationv v final 9 14-16
 
Final q2 fy16 quarterly earnings presentation
Final q2 fy16 quarterly earnings presentationFinal q2 fy16 quarterly earnings presentation
Final q2 fy16 quarterly earnings presentation
 
Investor presentations dec final
Investor presentations dec finalInvestor presentations dec final
Investor presentations dec final
 
2Q'17 Level 3 Earnings Presentation
2Q'17 Level 3 Earnings Presentation2Q'17 Level 3 Earnings Presentation
2Q'17 Level 3 Earnings Presentation
 
4 q15 slides _final.pptx
4 q15 slides _final.pptx4 q15 slides _final.pptx
4 q15 slides _final.pptx
 
southern 2006 4th
southern 2006 4thsouthern 2006 4th
southern 2006 4th
 
Teck’s Q2 2019 Financial Results and Investors’ Conference Call
Teck’s Q2 2019 Financial Results and Investors’ Conference CallTeck’s Q2 2019 Financial Results and Investors’ Conference Call
Teck’s Q2 2019 Financial Results and Investors’ Conference Call
 
BP 1Q 2020 Financial results
BP 1Q 2020 Financial results BP 1Q 2020 Financial results
BP 1Q 2020 Financial results
 
BP 3Q 2019 results presentation
 BP 3Q 2019 results presentation BP 3Q 2019 results presentation
BP 3Q 2019 results presentation
 

Andere mochten auch

TRC Q2 2017 Earnings Slides
TRC Q2 2017 Earnings SlidesTRC Q2 2017 Earnings Slides
TRC Q2 2017 Earnings Slidestrcsolutions
 
3.31.17 exas april 2017 corporate presentation
3.31.17   exas april 2017 corporate presentation3.31.17   exas april 2017 corporate presentation
3.31.17 exas april 2017 corporate presentationExact Sciences
 
3.31.17 exas april 2017 corporate presentation v2
3.31.17   exas april 2017 corporate presentation v23.31.17   exas april 2017 corporate presentation v2
3.31.17 exas april 2017 corporate presentation v2Exact Sciences
 
Mic q4 2016_earnings_presentation
Mic q4 2016_earnings_presentationMic q4 2016_earnings_presentation
Mic q4 2016_earnings_presentationgenworth_financial
 
2.21.17 exas corporate presentation - final
2.21.17   exas corporate presentation - final2.21.17   exas corporate presentation - final
2.21.17 exas corporate presentation - finalExact Sciences
 
Mas q4 2016 earnings presentation 02.09.2017
Mas q4 2016 earnings presentation 02.09.2017 Mas q4 2016 earnings presentation 02.09.2017
Mas q4 2016 earnings presentation 02.09.2017 Masco_Investors
 
Wrk mar 2017 investor presentation final
Wrk mar 2017 investor presentation finalWrk mar 2017 investor presentation final
Wrk mar 2017 investor presentation finalir_westrock
 
Q4 Slides 020917
Q4 Slides 020917Q4 Slides 020917
Q4 Slides 020917wuir
 
Symantec investor presentation february 2017
Symantec investor presentation february 2017Symantec investor presentation february 2017
Symantec investor presentation february 2017InvestorSymantec
 
Evaluation Question 2
Evaluation Question 2Evaluation Question 2
Evaluation Question 2j7ralph
 
Technology Enhanced Learning and Innovative pedagogy
Technology Enhanced Learning and Innovative pedagogyTechnology Enhanced Learning and Innovative pedagogy
Technology Enhanced Learning and Innovative pedagogyDavid Biggins
 
Italialaiset maaliskuu
Italialaiset maaliskuuItalialaiset maaliskuu
Italialaiset maaliskuuLaila Bröcker
 
3Com 03-0172-300
3Com 03-0172-3003Com 03-0172-300
3Com 03-0172-300savomir
 
3Com 1694-210-050-2.00
3Com 1694-210-050-2.003Com 1694-210-050-2.00
3Com 1694-210-050-2.00savomir
 

Andere mochten auch (20)

TRC Q2 2017 Earnings Slides
TRC Q2 2017 Earnings SlidesTRC Q2 2017 Earnings Slides
TRC Q2 2017 Earnings Slides
 
3.31.17 exas april 2017 corporate presentation
3.31.17   exas april 2017 corporate presentation3.31.17   exas april 2017 corporate presentation
3.31.17 exas april 2017 corporate presentation
 
3.31.17 exas april 2017 corporate presentation v2
3.31.17   exas april 2017 corporate presentation v23.31.17   exas april 2017 corporate presentation v2
3.31.17 exas april 2017 corporate presentation v2
 
Mic q4 2016_earnings_presentation
Mic q4 2016_earnings_presentationMic q4 2016_earnings_presentation
Mic q4 2016_earnings_presentation
 
Winter 2017 Investor Presentation
Winter 2017 Investor PresentationWinter 2017 Investor Presentation
Winter 2017 Investor Presentation
 
2.21.17 exas corporate presentation - final
2.21.17   exas corporate presentation - final2.21.17   exas corporate presentation - final
2.21.17 exas corporate presentation - final
 
Mas q4 2016 earnings presentation 02.09.2017
Mas q4 2016 earnings presentation 02.09.2017 Mas q4 2016 earnings presentation 02.09.2017
Mas q4 2016 earnings presentation 02.09.2017
 
Wrk mar 2017 investor presentation final
Wrk mar 2017 investor presentation finalWrk mar 2017 investor presentation final
Wrk mar 2017 investor presentation final
 
Q4 Slides 020917
Q4 Slides 020917Q4 Slides 020917
Q4 Slides 020917
 
Inge g-thulin ceo
Inge g-thulin ceoInge g-thulin ceo
Inge g-thulin ceo
 
Symantec investor presentation february 2017
Symantec investor presentation february 2017Symantec investor presentation february 2017
Symantec investor presentation february 2017
 
Dreamforce 2016 Investor Day
Dreamforce 2016 Investor DayDreamforce 2016 Investor Day
Dreamforce 2016 Investor Day
 
Question 1
Question 1Question 1
Question 1
 
Da vincicode
Da vincicodeDa vincicode
Da vincicode
 
Evaluation Question 2
Evaluation Question 2Evaluation Question 2
Evaluation Question 2
 
Technology Enhanced Learning and Innovative pedagogy
Technology Enhanced Learning and Innovative pedagogyTechnology Enhanced Learning and Innovative pedagogy
Technology Enhanced Learning and Innovative pedagogy
 
Italialaiset maaliskuu
Italialaiset maaliskuuItalialaiset maaliskuu
Italialaiset maaliskuu
 
Buscar v, filtros y macros
Buscar v, filtros y macrosBuscar v, filtros y macros
Buscar v, filtros y macros
 
3Com 03-0172-300
3Com 03-0172-3003Com 03-0172-300
3Com 03-0172-300
 
3Com 1694-210-050-2.00
3Com 1694-210-050-2.003Com 1694-210-050-2.00
3Com 1694-210-050-2.00
 

Ähnlich wie Du pont & fmc transactions presentation

Du pont 4q14 slides final
Du pont 4q14 slides finalDu pont 4q14 slides final
Du pont 4q14 slides finalDupontInv
 
Du pont 4q14 slides final
Du pont 4q14 slides finalDu pont 4q14 slides final
Du pont 4q14 slides finalDupontInv
 
Cagny presentation 2014 vfinal
Cagny presentation 2014 vfinalCagny presentation 2014 vfinal
Cagny presentation 2014 vfinalSysco_Investors
 
DuPont Fact Sheet
DuPont Fact SheetDuPont Fact Sheet
DuPont Fact SheetDupontInv
 
Sysco Investor Presentation CAGNY 2015
Sysco Investor Presentation  CAGNY 2015Sysco Investor Presentation  CAGNY 2015
Sysco Investor Presentation CAGNY 2015Sysco_Investors
 
Shire - The Path to US$10 Billion in Product Sales by 2020
Shire - The Path to US$10 Billion in Product Sales by 2020Shire - The Path to US$10 Billion in Product Sales by 2020
Shire - The Path to US$10 Billion in Product Sales by 2020Company Spotlight
 
Bmo presentation final-feb28-2022
Bmo presentation   final-feb28-2022Bmo presentation   final-feb28-2022
Bmo presentation final-feb28-2022AdnetNew
 
bp 1Q 2021 financial results
bp 1Q 2021 financial resultsbp 1Q 2021 financial results
bp 1Q 2021 financial resultsbp
 
Vitro Acquisition Investor Presentation_2015-05-13
Vitro Acquisition Investor Presentation_2015-05-13Vitro Acquisition Investor Presentation_2015-05-13
Vitro Acquisition Investor Presentation_2015-05-13Fabio Tichauer
 
Kindred Healthcare August 2011 Town Hall Meeting
Kindred Healthcare August 2011 Town Hall MeetingKindred Healthcare August 2011 Town Hall Meeting
Kindred Healthcare August 2011 Town Hall MeetingKindred Healthcare
 
2013 Wells Fargo Pipeline, MLP & Energy Symposium
2013 Wells Fargo Pipeline, MLP & Energy Symposium2013 Wells Fargo Pipeline, MLP & Energy Symposium
2013 Wells Fargo Pipeline, MLP & Energy SymposiumEnLinkMidstreamLLC
 
4 q16 presentation final
4 q16 presentation   final4 q16 presentation   final
4 q16 presentation finalaoncorp
 

Ähnlich wie Du pont & fmc transactions presentation (20)

Du pont 4q14 slides final
Du pont 4q14 slides finalDu pont 4q14 slides final
Du pont 4q14 slides final
 
Du pont 4q14 slides final
Du pont 4q14 slides finalDu pont 4q14 slides final
Du pont 4q14 slides final
 
February 9 2021 Investor Presentation
February 9 2021 Investor PresentationFebruary 9 2021 Investor Presentation
February 9 2021 Investor Presentation
 
CHK January 2021 Roadshow
CHK January 2021 RoadshowCHK January 2021 Roadshow
CHK January 2021 Roadshow
 
February 9 2021 Investor Presentation
February 9 2021 Investor PresentationFebruary 9 2021 Investor Presentation
February 9 2021 Investor Presentation
 
February 9 2021 Investor Presentation
February 9 2021 Investor PresentationFebruary 9 2021 Investor Presentation
February 9 2021 Investor Presentation
 
Cagny presentation 2014 vfinal
Cagny presentation 2014 vfinalCagny presentation 2014 vfinal
Cagny presentation 2014 vfinal
 
1Q 2021 Earnings Presentation
1Q 2021 Earnings Presentation1Q 2021 Earnings Presentation
1Q 2021 Earnings Presentation
 
1Q 2021 Earnings Presentation
1Q 2021 Earnings Presentation1Q 2021 Earnings Presentation
1Q 2021 Earnings Presentation
 
1Q 2021 Earnings Presentation
1Q 2021 Earnings Presentation1Q 2021 Earnings Presentation
1Q 2021 Earnings Presentation
 
February 2021 - Investor Presentation
February 2021 - Investor PresentationFebruary 2021 - Investor Presentation
February 2021 - Investor Presentation
 
DuPont Fact Sheet
DuPont Fact SheetDuPont Fact Sheet
DuPont Fact Sheet
 
Sysco Investor Presentation CAGNY 2015
Sysco Investor Presentation  CAGNY 2015Sysco Investor Presentation  CAGNY 2015
Sysco Investor Presentation CAGNY 2015
 
Shire - The Path to US$10 Billion in Product Sales by 2020
Shire - The Path to US$10 Billion in Product Sales by 2020Shire - The Path to US$10 Billion in Product Sales by 2020
Shire - The Path to US$10 Billion in Product Sales by 2020
 
Bmo presentation final-feb28-2022
Bmo presentation   final-feb28-2022Bmo presentation   final-feb28-2022
Bmo presentation final-feb28-2022
 
bp 1Q 2021 financial results
bp 1Q 2021 financial resultsbp 1Q 2021 financial results
bp 1Q 2021 financial results
 
Vitro Acquisition Investor Presentation_2015-05-13
Vitro Acquisition Investor Presentation_2015-05-13Vitro Acquisition Investor Presentation_2015-05-13
Vitro Acquisition Investor Presentation_2015-05-13
 
Kindred Healthcare August 2011 Town Hall Meeting
Kindred Healthcare August 2011 Town Hall MeetingKindred Healthcare August 2011 Town Hall Meeting
Kindred Healthcare August 2011 Town Hall Meeting
 
2013 Wells Fargo Pipeline, MLP & Energy Symposium
2013 Wells Fargo Pipeline, MLP & Energy Symposium2013 Wells Fargo Pipeline, MLP & Energy Symposium
2013 Wells Fargo Pipeline, MLP & Energy Symposium
 
4 q16 presentation final
4 q16 presentation   final4 q16 presentation   final
4 q16 presentation final
 

Mehr von DupontInv

Du pont 3q15 Slides Final
Du pont 3q15 Slides FinalDu pont 3q15 Slides Final
Du pont 3q15 Slides FinalDupontInv
 
Du pont 2q15 slides final
Du pont 2q15 slides finalDu pont 2q15 slides final
Du pont 2q15 slides finalDupontInv
 
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015DupontInv
 
Du pont 1q15 slides final
Du pont 1q15 slides finalDu pont 1q15 slides final
Du pont 1q15 slides finalDupontInv
 
Investor Presentation – April 2015
Investor Presentation – April 2015Investor Presentation – April 2015
Investor Presentation – April 2015DupontInv
 
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials ConferenceDuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials ConferenceDupontInv
 
Baml conference 2015 final
Baml conference 2015   finalBaml conference 2015   final
Baml conference 2015 finalDupontInv
 
DuPont Presents at Citi 2014 Basic Materials Conference
DuPont Presents at Citi 2014 Basic Materials ConferenceDuPont Presents at Citi 2014 Basic Materials Conference
DuPont Presents at Citi 2014 Basic Materials ConferenceDupontInv
 
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture ConferenceDuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture ConferenceDupontInv
 
Morgan Stanley Investor Presentation
Morgan Stanley Investor PresentationMorgan Stanley Investor Presentation
Morgan Stanley Investor PresentationDupontInv
 
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture ConferenceDuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture ConferenceDupontInv
 
Investor presentation final
Investor presentation   finalInvestor presentation   final
Investor presentation finalDupontInv
 
Du pont 3q14 slides final
Du pont 3q14 slides finalDu pont 3q14 slides final
Du pont 3q14 slides finalDupontInv
 
Credit Suisse Presentation, September 18 2014
Credit Suisse Presentation, September 18 2014Credit Suisse Presentation, September 18 2014
Credit Suisse Presentation, September 18 2014DupontInv
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDupontInv
 
2 q14 slides final
2 q14 slides final2 q14 slides final
2 q14 slides finalDupontInv
 
Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14DupontInv
 

Mehr von DupontInv (17)

Du pont 3q15 Slides Final
Du pont 3q15 Slides FinalDu pont 3q15 Slides Final
Du pont 3q15 Slides Final
 
Du pont 2q15 slides final
Du pont 2q15 slides finalDu pont 2q15 slides final
Du pont 2q15 slides final
 
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
 
Du pont 1q15 slides final
Du pont 1q15 slides finalDu pont 1q15 slides final
Du pont 1q15 slides final
 
Investor Presentation – April 2015
Investor Presentation – April 2015Investor Presentation – April 2015
Investor Presentation – April 2015
 
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials ConferenceDuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
 
Baml conference 2015 final
Baml conference 2015   finalBaml conference 2015   final
Baml conference 2015 final
 
DuPont Presents at Citi 2014 Basic Materials Conference
DuPont Presents at Citi 2014 Basic Materials ConferenceDuPont Presents at Citi 2014 Basic Materials Conference
DuPont Presents at Citi 2014 Basic Materials Conference
 
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture ConferenceDuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
 
Morgan Stanley Investor Presentation
Morgan Stanley Investor PresentationMorgan Stanley Investor Presentation
Morgan Stanley Investor Presentation
 
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture ConferenceDuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
 
Investor presentation final
Investor presentation   finalInvestor presentation   final
Investor presentation final
 
Du pont 3q14 slides final
Du pont 3q14 slides finalDu pont 3q14 slides final
Du pont 3q14 slides final
 
Credit Suisse Presentation, September 18 2014
Credit Suisse Presentation, September 18 2014Credit Suisse Presentation, September 18 2014
Credit Suisse Presentation, September 18 2014
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
 
2 q14 slides final
2 q14 slides final2 q14 slides final
2 q14 slides final
 
Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14
 

Kürzlich hochgeladen

Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023Deutsche EuroShop AG
 
Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024nicola_mining
 
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDFWWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDFMichael Claudio
 
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24Deutsche EuroShop AG
 
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024Osisko Gold Royalties Ltd
 
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper PotentialAdvancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper Potentialnicola_mining
 

Kürzlich hochgeladen (6)

Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023
 
Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024
 
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDFWWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
 
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24
 
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
 
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper PotentialAdvancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
 

Du pont & fmc transactions presentation

  • 1. Summary of Transactions with FMC: Divestiture of Certain Crop Protection Assets and Acquisition of FMC’s Health & Nutrition Business March 31, 2017
  • 2. 2 Cautionary Notes on Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward- looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed merger of equals transaction with The Dow Chemical Company (the “DowDuPont Merger”) and the proposed transaction with FMC Corporation (FMC) and the anticipated benefits thereof. These and other forward- looking statements, including the failure to consummate the DowDuPont Merger or the proposed transaction or to make or take any filing or other action required to consummate such transactions in a timely manner or at all, are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward- looking statements. Important risk factors that may cause such a difference include, but are not limited to, (i) the completion of the DowDuPont Merger and the proposed transaction on anticipated terms and timing, including obtaining regulatory approvals, anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the new combined company’s or the Health and Nutrition business’s operations and other conditions to the completion of the DowDuPont Merger and the proposed transaction, (ii) the possibility that the DowDuPont Merger and the proposed transaction may not close, including because the various approvals, authorizations and declarations of non-objections from certain regulatory and governmental authorities with respect to either the DowDuPont Merger or the proposed transaction may not be obtained, on a timely basis or otherwise, including that these regulatory or governmental authorities may not approve of FMC as an acceptable purchaser of the Ag business in connection with the proposed transaction or may impose conditions on the granting of the various approvals, authorizations and declarations of non-objections, including requiring the respective Dow, DuPont and FMC businesses, including the Health and Nutrition business (in the case of DuPont) and the Ag business (in the case of FMC), to divest certain assets if necessary to obtain certain regulatory approvals or otherwise limiting the ability of the combined company to integrate parts of the Dow and DuPont businesses and/or the DuPont and Health and Nutrition businesses, (iii) the ability of DuPont to integrate the Health and Nutrition business successfully and to achieve anticipated synergies, (iv) potential litigation or regulatory actions relating to the DowDuPont Merger or the proposed transaction that could be instituted against DuPont or its directors, (v) the risk that disruptions from the
  • 3. 3 Cautionary Notes on Forward Looking Statements, Continued DowDuPont Merger or the proposed transaction will harm DuPont’s business, including current plans and operations, (vi) the ability of DuPont to retain and hire key personnel, (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the DowDuPont Merger or the proposed transaction, (viii) uncertainty as to the long-term value of DowDuPont common stock, (ix) continued availability of capital and financing and rating agency actions, (x) legislative, regulatory and economic developments, (xi) potential business uncertainty, including changes to existing business relationships, during the pendency of the DowDuPont Merger or the proposed transaction that could affect DuPont’s financial performance, (xii) certain restrictions during the pendency of the DowDuPont Merger or the proposed transaction that may impact DuPont’s ability to pursue certain business opportunities or strategic transactions and (xiii) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associated with the DowDuPont Merger or the proposed transaction, are or will be more fully discussed in (1) DuPont’s most recently filed Form 10-K, 10-Q and 8-K reports, (2) DuPont’s subsequently filed Form 10-K and 10-Q reports and (3) the joint proxy statement/prospectus included in the Registration Statement filed with the SEC in connection with the DowDuPont Merger. While the list of factors presented here is, and the list of factors presented in the relevant Form 10-K, 10-Q and 8-K reports and the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. DuPont assumes no obligation to publicly provide revisions or updates to any forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Adjusted EBITDA Financial Information This document includes financial information described as “Adjusted EBITDA”, which is a financial term based on earnings before interest, taxes, depreciation and amortization. Adjusted EBTIDA does not conform to U.S. generally accepted accounting principles (GAAP) and is considered a non-GAAP measure. The Adjusted EBITDA presented represents management’s best estimate of 2016 financial performance for the portion of DuPont’s business to be divested inclusive of certain assumptions regarding allocations of costs and therefore a directly comparable measure that would be considered calculated and presented in accordance with GAAP is not available.
  • 4. 4 • DuPont to sell cereal broadleaf herbicides and chewing insecticides, together with certain crop protection R&D capabilities and early stage pipeline initiatives to FMC Corporation ("FMC") • DuPont to acquire substantially all of FMC’s Health & Nutrition business, including food ingredients and pharmaceutical excipients • DuPont to receive $1.6B from FMC reflecting difference in asset value; $1.2B in cash, $0.4B in working capital • Transactions contingent on DowDuPont merger of equals • Significant progress on DowDuPont merger of equals — Targeted merger to close by August 31, 2017 — Targeted close of transactions with FMC in 4Q 2017 — ~$3B of expected DowDuPont merger cost synergies and $1B of growth synergies preserved Summary of Transactions1 FMC Health & Nutrition 2016 Sales: $707MM 2016 Adjusted EBITDA2: $228MM Select Herbicides Select Insecticides Certain Crop Protection R&D Capabilities and Early Stage Discovery Pipeline 2016 Sales: ~$1.4B 2016 Adjusted EBITDA3: ~$450MM 1 Subject to satisfaction of closing conditions, including receipt of regulatory approval 2 Based on information as disclosed in FMC’s 2016 Form 10-K filing. EBITDA is calculated based upon 2016 FMC’s H&N operating profit less segment depreciation & amortization. 3 Adjusted EBITDA represents management’s estimate of 2016 earnings for the product lines and R&D organization and pipeline, including certain allocations, to be divested before interest, taxes, depreciation & amortization. $1.625B = Difference in asset value Cash Payment to DuPont by FMC 1,200$ DuPont Retains Certain Working Capital ~425 Consideration to DuPont in Addition to FMC's H&N business 1,625$ Transaction Economics ($MM)
  • 5. 5 DowDuPont’s Strong Global Pure-Play Agriculture Business Dow Agriculture DuPont Agriculture Crop Protection Seeds & Traits DuPont Agriculture Planned Divestiture 2016 Sales $1.4B 1Based on net sales as reported in DuPont’s and Dow’s respective 2016 Form 10-K filings. 2 Late stage defined as pipeline in the following phases: (3) Advanced Development, (4) Pre-Launch, and (L) Launch, as outlined in the presentation at the Bank of America Merrill Lynch conference on March 1, 2017. Crop ProtectionSeeds & Traits DuPont Agriculture Dow Agriculture Agriculture Business Before Planned Divestiture 2016 Net Sales1: $15.7B Agriculture Business After Planned Divestiture 2016 Net Sales1: $14.3B DowDuPont’s Agriculture Business Will Have: — A strong, balanced, pure-play profile with a comprehensive and diverse seed, trait, and crop protection portfolio and exceptional growth opportunity — Strong IP-protected portfolio of crop protection assets, including insect control, cereal weed control, broadleaf and grass control, and disease control — Industry-leading soy and corn selective herbicide offering and strong market share position in cereal crops — Integrated approach to increase crop productivity by leveraging innovative technologies on a foundation of agronomic, biotechnology, and digital solutions — Enhanced scale, multiple routes-to-market enabling deeper customer intimacy and delivery of complete crop productivity solutions Planned Divestiture to Include: — DuPont’s cereal broadleaf herbicides portfolio — DuPont’s chewing insecticides portfolio: Rynaxypyr®, Cyazypyr® and Indoxacarb — DuPont’s Crop Protection research and development pipeline and organization, excluding seed treatment, nematicides, and late-stage R&D programs1, which DuPont will continue to develop and bring to market, and excluding personnel needed to support marketed products and R&D programs that will remain with DuPont
  • 6. 6  1. This product is fully approved in the U.S. and Canada. Traits included in these products may or may not be approved in all global markets. Combination Creates Step-Change Capability to Drive Crop Productivity Strong portfolio of seed and crop protection solutions to increase grower profitability CropProtectionGermplasm/Traits Seed Brands Traits InsecticidesHerbicides Fungicides Other Offerings Advanced Technologies Specialty Insect Control Portfolio 1  Planned divestiture maintains the strategic logic and value creation potential of the merger Broad Seed Offering to Drive Yield Improvements — Leading seed portfolio based on elite germplasm delivered through traditional and advanced breeding techniques — Strong, diverse trait offerings Innovative Crop Protection Portfolio — Broad portfolio of herbicide, insecticide, and fungicide offerings — Comprehensive pipeline addressing global resistance — Leadership position in diverse markets globally Expanding Portfolio of Diverse Technologies — Robust seed treatment offering leveraging seed, crop protection and development expertise — Prominent digital ag offering providing solid grower returns
  • 7. 7  High-margin, high-quality business exposed to attractive demographic macro tailwinds in Health & Nutrition  Products for nutrition market providing texture, structure and physical stability solutions that thicken and stabilize food products  Formulation ingredients serving the health excipient industry that function as binders, disintegrants and controlled-release compounds  Complementary businesses with new opportunities for growth  Greater offerings within DuPont’s existing texturants business; provides expertise in key areas such as cellulosics and expanded raw material access  Diversifies DuPont’s N&H portfolio via addition of pharmaceutical excipients platform; brings market and customer access to pharmaceutical industry  Creates opportunities for incremental synergies for Specialty Products Transaction Strengthens DowDuPont’s Innovation-Driven Specialty Products Platform 2016 Net Sales1 FMC Health & Nutrition2 Nutrition Ingredients Health Excipients ~$0.7B Functional Health Ingredients ~$0.2B EBITDA Electronics & Communications Industrial BiosciencesProtection Solutions Nutrition & Health ~$3B Aramids Nonwovens Solid Surfaces ~$1.5B Enzymes Biomaterials ~$4B Nutrition Health FMC H&N Process Technologies 1 Based on net sales as reported in DuPont’s and Dow’s respective 2016 Form 10-K filings. 2 Based on information as disclosed in FMC’s 2016 Form 10-K filing. EBITDA is calculated based upon 2016 FMC’s H&N operating profit less segment depreciation & amortization. ~$4B
  • 8. 8 Specialty Products to Capitalize on Global Megatrends to Deliver Organic Growth Across Portfolio Resulting in the need for… Engineered materials that protect people, processes and the environment Biotechnology solutions for large-scale industrial processes Key Global Megatrends Leading Positions • Aramid fibers and paper • Nonwoven films and fabrics • Protective garments • Industrial enzymes • Advanced biofuels • Sulfuric acid technology Electronic materials that enable miniaturization, connectivity and versatility • Solar PV materials • Circuit packaging materials • Semicon fab materials Safe, nutritious and healthy foods • Probiotics & cultures • Systems and texturants • Specialty proteins Electronics & Communications Industrial Biosciences Protection Solutions Nutrition & Health Connectivity and functionality Protection and sustainable development Emerging needs in new geographies Improved health and nutrition Renewable energy and materials
  • 9. 9 Copyright © 2017 DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and all products, unless otherwise noted, denoted with ® or TM are trademarks or registered trademarks of E. I. du Pont de Nemours and Company. +Images reproduced by E. I. du Pont de Nemours and Company under license from the National Geographic Society.